Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Reads0
Chats0
TLDR
Recent discoveries of new mechanisms underlying angiogenesis are examined, successes and challenges of current antiangiogenic therapy are discussed, and emerging antiangIogenic paradigms are highlighted.Abstract:
Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.read more
Citations
More filters
Journal Article
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
Journal ArticleDOI
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie Tung-Ping Poon,Kwang Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie Aude Le Berre,Gerold Meinhardt,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
Journal Article
Revisiting the hallmarks of cancer.
Yousef A. Fouad,Carmen Aanei +1 more
TL;DR: This work defines seven hallmarks of cancer: selective growth and proliferative advantage, altered stress response favoring overall survival, vascularization, invasion and metastasis, metabolic rewiring, an abetting microenvironment, and immune modulation, while highlighting some considerations for the future of the field.
Journal ArticleDOI
Fatty acid carbon is essential for dNTP synthesis in endothelial cells
Sandra Schoors,Ulrike Bruning,Rindert Missiaen,Karla C. S. Queiroz,Gitte Borgers,Ilaria Elia,Annalisa Zecchin,Anna Rita Cantelmo,Stefan Christen,Jermaine Goveia,Ward Heggermont,Lucica Godde,Stefan Vinckier,Paul P. Van Veldhoven,Guy Eelen,Luc Schoonjans,Holger Gerhardt,Mieke Dewerchin,Myriam Baes,Katrien De Bock,Bart Ghesquière,Sophia Y. Lunt,Sarah-Maria Fendt,Peter Carmeliet +23 more
TL;DR: It is reported that endothelial loss of CPT1A, a rate-limiting enzyme of fatty acid oxidation (FAO), causes vascular sprouting defects due to impaired proliferation, not migration, of human and murine endothelial cells.
Journal ArticleDOI
Endothelial cell metabolism in normal and diseased vasculature
TL;DR: How EC metabolism differs between the normal and dysfunctional/diseased vasculature and how it relates to or affects the metabolism of other cell types contributing to the pathology is reviewed.
References
More filters
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet,Rakesh K. Jain +1 more
TL;DR: Preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
Related Papers (5)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet,Rakesh K. Jain +1 more